Sarepta Therapeutics Inc (SRPT) - News Archive

Sarepta Therapeutics: Anticipating a Turnaround Amidst Financial Challenges CAMBRIDGE, Mass. Barricading the turbulent tides of fiscal challenges, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a pioneer in precision geneti...

In the world of biopharmaceuticals, the intersection of innovative therapies and robust financial health is critical for sustained growth and development. Recent developments at Sarepta Therapeutics, a leader in precisi...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a company specializing in precision genetic medicine for rare diseases, has recently gained attention due to two significant developments. On one hand, the company provided a st...

Class Action Lawsuit Alert: Sarepta Therapeutics Investors Under the Microscope as Pomerantz LLP Takes Legal Action Overview In a series of unfolding legal developments, Pomerantz LLP, a reputable law firm specializing...

CAMBRIDGE, Mass. Sarepta Therapeutics, Inc. (NASDAQ: SRPT), renowned for its pioneering work in precision genetic medicine for rare diseases, recently announced that the rAAVrh74 viral vector utilized in its investigati...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a prominent player in the biotechnology sector, is attracting attention amidst growing investor concerns. As of the latest reports, the company’s shares are currently trading a...

Advances in Gene Therapy: Sarepta Therapeutics ELEVIDYS and Strategic Growth Initiatives Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a frontrunner in precision genetic medicine for rare diseases, has made significant str...

CAMBRIDGE, Mass. Sarepta Therapeutics, Inc. (NASDAQ:SRPT), renowned for leading advancements in precision genetic medicine tailored for rare diseases, has recently released an important update on its pioneering gene the...

In a vibrant start to the trading week, Monday, March 31, 2025, saw U.S. stock markets bask in green, signaling a robust kickoff to the spring quarter.

Sarepta Therapeutics: Leading the Charge in Precision Genetic Medicine with Remarkable Growth and Innovation Sarepta Therapeutics, Inc. (NASDAQ: SRPT), an innovative leader in precision genetic medicine focused on rare...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has demonstrated substantial financial and strategic growth in the third quarter of 2024. This article analyzes the re...

Sarepta Therapeutics Executes Inducement Grants for Strategic Talent Acquisition Under Nasdaq Rule 5635(c)(4) In a strategic move aimed at fortifying its competitive edge in the rapidly evolving field of precision genet...

Harnessing the Power of Precision Medicine: Sarepta Therapeutics and Arrowhead Pharmaceuticals Forge Strategic Alliance Amidst Record-Breaking Financial Performance Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a trailblaz...

: Sarepta Therapeutics, a trailblazer in the realm of precision genetic medicine, made a significant stride in fortifying its workforce and commitment to therapeutic innovations by granting equity awards under Nasdaq Li...

Precision Medicine Moves Forward: Sarepta Therapeutics Announces Inducement Grants and Continued Market Success In a bold stride towards bolstering its talent pool and reaffirming its industry prowess, Sarepta Therapeut...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), continues to forge ahead as a paragon in the field of precision genetic medicine for rare diseases. The recent announcements regarding corporate developments, presentation of ne...

In the esteemed town of Cambridge, Massachusetts, on the thirtieth day of September in the year of our Lord two thousand and twenty-four, the illustrious institution, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), hath made...

In the rapidly evolving landscape of genetic medicine, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a frontrunner in precision therapies for rare diseases, is set to make significant waves at the upcoming 29th Annual Congr...

Sarepta Therapeutics Reports Significant Milestones and Expands Workforce with New Inducement Grants in Q2 2024 Sarepta Therapeutics, Inc., a pioneer in precision genetic medicine for rare diseases, has published its fi...

Sarepta Therapeutics to Release Q2 2024 Financial Results, Hosting Conference Call for Investors Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a prominent player in the realm of precision genetic medicine focused on rare di...